BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Odyssey Thera, Inc. Announces New Equity Financing New Funds to Help Guide the Next Stage of Company's Development


10/7/2008 9:26:37 AM

SAN RAMON, Calif., Oct. 7 /PRNewswire/ -- Odyssey Thera, Inc. announced today a new equity financing, with Merck and Co., Inc. as one of the investors. Existing investors Burrill & Company, HBM Partners, and Healthcap also participated. The funds will be used to support continued advancement of Odyssey Thera's technologies and products. This is the first close of the current financing round, which will remain open through the end of 2008.

Hugh Rienhoff, M.D., a San Francisco Bay area physician and entrepreneur, will serve as chairman of Odyssey Thera's board of directors. Dr. Rienhoff stated, "The Company has reached several significant milestones. Odyssey Thera's technology platform has been embraced by many of the world's leading pharmaceutical companies, and our cumulative expertise is a significant enabler in the drug development process -- for our partners and for Odyssey Thera."

In connection with the financing, Alan Sachs, M.D., Ph.D., Vice President of RNA Therapeutics for Merck Research Laboratories, was elected to the Odyssey Thera board of directors.

"This investment from Merck and continuing support from current investors validates Odyssey Thera's scientific and business plans," said Dr. John K. Westwick, President and CEO of Odyssey Thera. "We look forward to applying our unique and proprietary technologies to develop our pipeline and to support Merck programs, with the aim of advancing multiple commercial opportunities."

About Odyssey Thera, Inc.

Odyssey Thera's patented technology measures disease-relevant pathway activity within living human cells. Rapid identification of on-target and off-pathway activities of lead compounds enables selection of drug candidates with optimal efficacy and safety profiles. The Company's leadership position in fundamental patents, technology, and know-how relating to cellular analysis has enabled it to form major alliances with leading companies including Pfizer, Abbott, and Merck. Odyssey Thera is also leveraging its proprietary drug discovery and development platform for internal programs. To learn more about Odyssey Thera, please visit http://www.odysseythera.com.

CONTACT: John Westwick of Odyssey Thera, Inc., +1-925-242-5011

Web site: http://www.odysseythera.com/



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES